People · Operator
Named in public records as an officer, director or promoter · active 2012–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Balance Therapeutics, Inc. | — | Biotechnology | Series B | $21.2M | $7.3M | 2015 |
| Kindred Biosciences, Inc. | — | Biotechnology | Series A | $14.8M | $192.0M | 2012 |
| Bio Usawa Inc. | — | Biotechnology | Seed | $2.6M | $1.2M | 2024 |
| Vetmab Biosciences, Inc. | — | Biotechnology | Seed | $2.6M | $3.9M | 2023 |
Richard Chin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Richard Chin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Denise Bevers | 2 | 3 |
| Michael Grey | 1 | 10 |
| Ernest Mario | 1 | 9 |
| Menghis Bairu | 1 | 2 |
| Phyllis E. Whiteley | 1 | 2 |
| Hangjun Zhan | 1 | 1 |
| Hangjun Marie Zhan | 1 | 1 |
| Richard Marie Chin | 1 | 1 |
| Denise Marie Bevers | 1 | 1 |
| Peter E. Carlton | 1 | 1 |
| Lyndon Lien | 1 | 1 |
| Ervin Vezspremi | 1 | 1 |
| Stephen Sundlof | 1 | 1 |
| Vincent Ancinetti | 1 | 1 |
| John Hautman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.